Cartesian Therapeutics's earnings have been declining at an average annual rate of -74.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 33.1% per year.
Key information
-74.1%
Earnings growth rate
-50.8%
EPS growth rate
Biotechs Industry Growth
-14.6%
Revenue growth rate
-33.1%
Return on equity
-32,557.0%
Net Margin
-589.1%
Last Earnings Update
30 Sep 2024
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Cartesian Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
DB:1S70 Revenue, expenses and earnings (USD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Sep 24
48
-282
39
0
30 Jun 24
54
-267
39
0
31 Mar 24
26
-288
38
0
31 Dec 23
26
-257
35
0
30 Sep 23
127
-1
41
0
31 Dec 22
111
35
24
0
31 Dec 21
85
-26
21
0
Quality Earnings: 1S70 is currently unprofitable.
Growing Profit Margin: 1S70 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 1S70's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 1S70's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1S70 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-21.2%).
Return on Equity
High ROE: 1S70 has a negative Return on Equity (-32557.05%), as it is currently unprofitable.